Based on this, and since different TOP1 inhibitors are used clinically for the treatment of small-cell lung, ovarian, and cervical cancer [43], their use in combination with 17-AAG or IPI-504 could be an interesting therapeutic strategy to be tested in lung adenocarcinoma patients presenting with high TOP1 expression. The gene discussed is TOP1; the disease is cervical cancer.